After U.S. Food and Drug Administration approval of its Argus IIs Retinal Prosthesis System on March 5, Second Sight Medical Products Inc. enjoyed an explosive stock surge, with shares gaining by 1000 percent in the next three days. ...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 26 biweekly issues
  • Subscriber-only digital content for prime stories
  • Book of Lists — the most comprehensive business resource in the Valley region
Yours for only $49